17 - 23 June 2017
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
MRI scans and disability levels
American research found that about one in eight people had a mismatch between their level of disability and the number of lesions seen on an MRI scan - either low lesion load and high disability (more likely in people with progressive MS) or many lesions but low disability. Researchers speculate that this last group may have more cognitive issues
Source: MS News Today
MS Trust link: MRI scans
European vaccine ruling
The European Court of Justice has ruled that vaccines can be considered the cause of subsequent illness even in the absence of any research evidence to support this. The case was prompted by someone in France who developed MS following a vaccination for hepatitis B
MS Trust link: Hepatitis B vaccine
Ocrevus and disease activity
Results to be presented at the European Academy of Neurology (EAN) meeting show that people with either relapsing or primary progressive MS taking Ocrevus (ocrelizumab) were more likely to maintain NEPAD over 96 weeks. NEPAD (an extended version of NEDA) indicates no relapses, no EDSS progression, no new lesions on MRI, and no or small increases in measures of walking and dexterity.
MS Trust link: Ocrevus (ocrelizumab)